A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
NCT ID: NCT04976322
Last Updated: 2025-12-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
PHASE3
760 participants
INTERVENTIONAL
2021-07-27
2030-08-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dapirolizumab pegol
Subjects will receive dapriolizumab pegol throughout the Treatment Period.
Dapirolizumab pegol
Subjects will receive dapirolizumab pegol at prespecified time-points.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dapirolizumab pegol
Subjects will receive dapirolizumab pegol at prespecified time-points.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The participant completed one of the parent studies within 4 weeks prior to entry to this study
Exclusion Criteria
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UCB Biopharma SRL
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
UCB Cares
Role: STUDY_DIRECTOR
001 844 599 2273 (UCB)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sl0046 50140
Birmingham, Alabama, United States
Sl0046 50328
Tucson, Arizona, United States
Sl0046 50383
Beverly Hills, California, United States
Sl0046 50275
La Palma, California, United States
Sl0046 50316
San Leandro, California, United States
Sl0046 50339
Denver, Colorado, United States
Sl0046 50239
Brandon, Florida, United States
Sl0046 50362
Gainesville, Florida, United States
Sl0046 50681
Miami, Florida, United States
Sl0046 50059
Ormond Beach, Florida, United States
Sl0046 50324
Plantation, Florida, United States
Sl0046 50329
Tampa, Florida, United States
Sl0046 50368
Atlanta, Georgia, United States
Sl0046 50240
Idaho Falls, Idaho, United States
Sl0046 50474
Hopkinsville, Kentucky, United States
Sl0046 50285
Lake Charles, Louisiana, United States
Sl0046 50015
Hagerstown, Maryland, United States
Sl0046 50219
Detroit, Michigan, United States
Sl0046 50273
Las Vegas, Nevada, United States
Sl0046 50366
Canton, New York, United States
Sl0046 50334
New York, New York, United States
Sl0046 50238
Charlotte, North Carolina, United States
Sl0046 50147
Hershey, Pennsylvania, United States
Sl0046 50001
Jackson, Tennessee, United States
Sl0046 50418
Colleyville, Texas, United States
Sl0046 50050
Beckley, West Virginia, United States
Sl0046 60002
Buenos Aires, , Argentina
Sl0046 60029
Mendoza, , Argentina
Sl0046 60003
Quilmes, , Argentina
Sl0046 60022
Quilmes, , Argentina
Sl0046 60011
San Juan, , Argentina
Sl0046 60014
San Miguel de Tucumán, , Argentina
Sl0046 40123
Brussels, , Belgium
Sl0046 40189
Plovdiv, , Bulgaria
Sl0046 40380
Sofia, , Bulgaria
Sl0046 50374
Calgary, , Canada
Sl0046 50337
Edmonton AB, , Canada
Sl0046 50259
Rimouski, , Canada
Sl0046 50045
Toronto, , Canada
Sl0046 60015
Santiago, , Chile
Sl0046 60018
Santiago, , Chile
Sl0046 60013
Barranquilla, , Colombia
Sl0046 60019
Barranquilla, , Colombia
Sl0046 60006
Bogotá, , Colombia
Sl0046 60027
Bogotá, , Colombia
Sl0046 60016
Bucaramanga, , Colombia
Sl0046 60007
Chía, , Colombia
Sl0046 60031
Montería, , Colombia
Sl0046 40066
Prague, , Czechia
Sl0046 40386
Cologne, , Germany
Sl0046 40072
Freiburg im Breisgau, , Germany
Sl0046 40027
Herne, , Germany
Sl0046 40078
Leipzig, , Germany
Sl0046 40402
Tübingen, , Germany
Sl0046 40378
Athens, , Greece
Sl0046 40501
Athens, , Greece
Sl0046 40377
Crete, , Greece
Sl0046 40507
Larissa, , Greece
Sl0046 40412
Budapest, , Hungary
Sl0046 40411
Debrecen, , Hungary
Sl0046 40031
Szeged, , Hungary
Sl0046 40499
Székesfehérvár, , Hungary
Sl0046 40084
Catania, , Italy
Sl0046 40448
Milan, , Italy
Sl0046 50317
Chihuahua City, , Mexico
Sl0046 50250
Cuernavaca, , Mexico
Sl0046 50249
Guadalajara, , Mexico
Sl0046 50271
León, , Mexico
Sl0046 50252
Mérida, , Mexico
Sl0046 50251
Monterrey, , Mexico
Sl0046 60009
Lima, , Peru
Sl0046 60023
Lima, , Peru
Sl0046 20182
Davao City, , Philippines
Sl0046 20181
Makati, , Philippines
Sl0046 40482
Bialystok, , Poland
Sl0046 40119
Bydgoszcz, , Poland
Sl0046 40398
Katowice, , Poland
Sl0046 40502
Krakow, , Poland
Sl0046 40151
Lublin, , Poland
Sl0046 40044
Poznan, , Poland
Sl0046 40090
Poznan, , Poland
Sl0046 40097
Warsaw, , Poland
Sl0046 40098
Warsaw, , Poland
Sl0046 40397
Wroclaw, , Poland
Sl0046 40481
Wroclaw, , Poland
Sl0046 40382
Galati, , Romania
Sl0046 40393
Belgrade, , Serbia
Sl0046 40461
Belgrade, , Serbia
Sl0046 20108
Incheon, , South Korea
Sl0046 20104
Seoul, , South Korea
Sl0046 40160
Barcelona, , Spain
Sl0046 40341
Málaga, , Spain
Sl0046 40101
Sabadell, , Spain
Sl0046 40099
Vigo, , Spain
Sl0046 20113
Taichung, , Taiwan
Sl0046 20142
Taichung, , Taiwan
Sl0046 20095
Taipei, , Taiwan
Sl0046 20082
Taiyuan, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-003409-83
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
U1111-1293-7098
Identifier Type: OTHER
Identifier Source: secondary_id
2023-506368-14
Identifier Type: REGISTRY
Identifier Source: secondary_id
SL0046
Identifier Type: -
Identifier Source: org_study_id